The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).

Support Care Cancer · 2022 · PMC8935622 · PMID 35312857

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

borderline significantP = 0.058so close (0.05 < p ≤ 0.1)

In addition, Table 2 shows a borderline significant difference in pain level at follow-up between both groups, with a higher score in the control group ( P = 0.058).

also in 11,409 other papers

showed a trendno p-value reported

Although not significant, a visual analysis showed a trend in which the control group appears to have a higher mTNS at the end of chemotherapy and follow-up than the PBM group (Fig. 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.